Profil
Robert E.
Winkler worked as Vice President of Clinical Research & Development at Array BioPharma, Inc. He then worked as Vice President of Clinical Research & Operations at Amicus Therapeutics, Inc. from 2011 to 2013.
In 2018, he became the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. Dr. Winkler received his undergraduate and doctorate degrees from The Hebrew University Hadassah Medical School.
Anciens postes connus de Robert E. Winkler
| Sociétés | Poste | Fin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 19/03/2020 |
| AMICUS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2013 |
| ARRAY TECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Robert E. Winkler
| The Hebrew University Hadassah Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
